P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
The genome of the western clawed frog xenopus tropicalis
Uffe Hellsten,Richard M. Harland,Michael J. Gilchrist,David A. Hendrix,Jerzy Jurka,Vladimir V. Kapitonov,Ivan Ovcharenko,Nicholas H. Putnam,Shengqiang Shu,Leila Taher,Ira L. Blitz,Bruce Blumberg,Darwin S. Dichmann,Inna Dubchak,Enrique Amaya,John C. Detter,Russell B. Fletcher,Daniela S. Gerhard,David Goodstein,Tina Graves,Igor V. Grigoriev,Jane Grimwood,Takeshi Kawashima,Takeshi Kawashima,Erika Lindquist,Susan Lucas,Paul E. Mead,Therese Mitros,Hajime Ogino,Yuko Ohta,Alexander Poliakov,Nicolas Pollet,Jacques Robert,Asaf Salamov,Amy K. Sater,Jeremy Schmutz,Astrid Terry,Peter D. Vize,Wesley C. Warren,Dan E. Wells,Andrea E. Wills,Richard K. Wilson,Lyle B. Zimmerman,Aaron M. Zorn,Robert M. Grainger,Timothy C. Grammer,Mustafa K. Khokha,Paul G. Richardson,Daniel S. Rokhsar,Daniel S. Rokhsar +49 more
TL;DR: The western clawed frog Xenopus tropicalis is an important model for vertebrate development that combines experimental advantages of the African clawed frogs Xenopus laevis with more tractable genetics.
Journal ArticleDOI
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
Dharminder Chauhan,Laurence Catley,Guilan Li,Klaus Podar,Teru Hideshima,Mugdha Velankar,Constantine S. Mitsiades,N. Mitsiades,Hiroshi Yasui,Anthony Letai,Huib Ovaa,Celia R. Berkers,Benjamin Nicholson,Ta-Hsiang Chao,Saskia T. C. Neuteboom,Paul G. Richardson,Michael A. Palladino,Kenneth C. Anderson +17 more
TL;DR: It is shown that the novel proteasome inhibitor NPI-0052 induces apoptosis in MM cells resistant to conventional and Bortezomib therapies, which provides the rationale for clinical protocols evaluating NPI -0052, alone and together with Bortzomib, to improve patient outcome in MM.
Journal ArticleDOI
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
Robert A. Kyle,Brian G.M. Durie,S V Rajkumar,Ola Landgren,J. Bladé,Giampaolo Merlini,N Kröger,H. Einsele,David H. Vesole,Meletios A. Dimopoulos,J F San Miguel,Hervé Avet-Loiseau,Roman Hájek,Wenming Chen,Kenneth C. Anderson,Heinz Ludwig,Pieter Sonneveld,Santiago Pavlovsky,Antonio Palumbo,Paul G. Richardson,Bart Barlogie,P R Greipp,Robert Vescio,Ingemar Turesson,Jan Westin,Mario Boccadoro +25 more
TL;DR: Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of residents of Olmsted County, Minnesota, 50 years of age or older and is characterized by having an M protein <15 g/l, IgG type and a normal free light chain (FLC) ratio.
Journal ArticleDOI
Reverse methanogenesis: testing the hypothesis with environmental genomics.
Steven J. Hallam,Nik Putnam,Christina M. Preston,John C. Detter,Daniel S. Rokhsar,Paul G. Richardson,Edward F. DeLong +6 more
TL;DR: Genetic analyses of methane-oxidizing Archaea from deep-sea sediments show that nearly all genes typically associated with methane production are present in one specific group of archaeal methanotrophs, which supports previous hypotheses and provides an informed foundation for metabolic modeling of anaerobic methane oxidation.
Journal ArticleDOI
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Shaji Kumar,Je-Hwan Lee,J. J. Lahuerta,Gareth J. Morgan,Paul G. Richardson,John Crowley,Jeffrey Haessler,John Feather,Antje Hoering,Philippe Moreau,Xavier Leleu,C. Hulin,S. K. Klein,Pieter Sonneveld,David S. Siegel,J. Bladé,H. Goldschmidt,Sundar Jagannath,Jesús F. San Miguel,Robert Z. Orlowski,Antonio Palumbo,O. Sezer,S V Rajkumar,Brian G.M. Durie +23 more
TL;DR: The median overall survival and event-free survival from T0 were 9 and 5 months, respectively, which confirms the poor outcome, once patients become refractory to current treatments.